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Conclusion: The alpha version of the tool is a first step 
towards its implementation in the clinical practice. The tool 
will be tested further by patients, to investigate whether it 
(a) influences the quality of the decision; (b) can be used 
without support. The tool is available in Dutch, English and 
Italian. Future efforts include the development of decision 
tools for other primary tumors. 
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Purpose or Objective: The increased use of magnetic 
resonance imaging (MRI) for radiotherapy (RT) target 
delineation has encouraged method development to enable 
the entire RT treatment planning workflow based on MRI 
only. Earlier we have presented a procedure for MRI only 
based treatment planning replacing planning CT in all phases 
of RT including simulation, target volume definition, dose 
calculation based on a pseudo-CT image set generated from 
MRI, and image guidance where comparison between MR or 
pseudo-CT reference set and MV/kV planar images or cone-
beam CT is performed. The method has been applied 
clinically for RT planning of localized prostate cancer since 
November, 2012. Here we present our early clinical 
experience. 
 
Material and Methods: We have followed n = 125 patients 
treated with MRI only procedure with serum prostate-specific 
antigen (PSA) at the beginning (baseline) and end of the RT 
course. As a reference, similar group of patients has been 
chosen where RT were planned with similar irradiation 
technique, margins, dosage (prostate 76 Gy in 2 Gy fractions, 
seminal vesicles 66 Gy in 2 Gy fractions) and image guidance 
method (gold seeds + daily kV/MV imaging), but where CT 
planning image set has been used as a primary data set in 
treatment planning and IGRT, and MRI images were 
registered to CT for target delineation. For the reference 
group, equal number of patients with additional antiandrogen 
therapy (n = 100) or RT only (n = 25) were chosen. 
 
Results: Mean PSA values for all the patient subgroups are 
presented in Table 1. The two methods show equal early 
response in PSA. No difference in early toxicity was noticed 
between the MRI only and CT+MRI groups. 
 
 
 
Conclusion: MRI only based RT treatment planning gave 
expected and equivalent results after RT compared with CT 
(MRI registered) based treatment planning procedure. Longer 
follow-up is needed to confirm the clinical equivalence 
related both to tumour response and normal tissue toxicity. 
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Purpose or Objective: On the basis of radiobiological studies 
suggesting a low α/β ratio for prostate adenocarcinoma, 
hypofractionation has been proposed to improve outcome in 
localized prostate cancer. STIP trial is a single center 
prospective phase I/II trial, with the aim of investigating 
feasibility and safety of moderate hypofractionation in low 
and intermediate risk (LR and IR) prostate cancer with Helical 
Tomotherapy (HT). We report early results in the first twelve 
recruited patients. 
 
Material and Methods: Inclusion criteria are: histologically 
confirmed adenocarcinoma, age ≥ 18  and ≤ 85 years, LR and 
IR according to NCCN, performance status (Karnofsky) ≥ 60, 
no clinical or radiological sign of metastasis, International 
Prostate Symptom Score (IPSS) ≤ 19, no previous cancer 
history.The addition of short-term Androgen Deprivation 
Therapy to radiation is prescribed for IR patients and 
performed for 6 months. CT/MR simulation and all treatment 
sessions were performed with empty rectum and comfortably 
full bladder. Clinical target volume (CTV) 1 comprised the 
prostate gland in 11 LR patients, CTV2 also included the 
seminal vesicles in one IR patient. Planning target volumes 
(PTV) 1 and 2 were defined, respectively, as CTV1 and 2 plus 
a 0.5 cm margin. Total doses of 60 Gy and 54 Gy were 
delivered, in 20 fractions, to PTV1 and 2, respectively. To 
compare CTVs and PTVs obtained with CT and MRI, these 
volumes were contoured on CT scans and then on the merged 
image sets. Before each fraction, daily megavoltage 
tomography (MCVT) was performed to reduce interfraction 
uncertainties. 
 
Results: Median follow-up was 12 months (range 3–20 
months). Mean dose to PTV1 was 60.15 Gy ( range 59.98-
60.27), mean dose to PTV2 was 54.65 Gy. According to CTCAE 
3.0 scale, acute G1 and G2 gastrointestinal toxicity occurred 
in 3 (25%) and 1 (8%) patients, respectively; no patients 
experienced G3 toxicity. G1 genitourinary toxicity occurred 
in 6 (50%) patients and no G2 or higher grade side effects 
were observed. According to the Expanded Prostate Cancer 
Index Composite (EPIC) questionnaire, urinary function 
declined 3 months post-treatment but it was similar to 
baseline at 12 months; bowel related quality of life remained 
stable during follow-up. IPSS remained similar to baseline for 
all patients. The contoured volume analysis showed that CTV 
and PTV based on MRI were always lower than CT based 
volumes (mean 38.07-87.10 vs 50.84-106). No patients 
experienced biochemical failure during follow-up. 
 
Conclusion: Our preliminary data support the safety of a 20-
fraction hypofractionated schedule delivered with HT in 
patients with localized prostate cancer. 
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Purpose or Objective: Carbon ion is characterized by unique 
physical and biological properties which is expected to be 
suitable to treat localized prostate cancer. In order to assess 
validate the feasibility and efficacy of carbon-ion 
radiotherapy for prostatic cancer, we synthesize and 
